School of Medicine
Showing 41-60 of 955 Results
-
Themistocles (Tim) Assimes
Associate Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsGenetic Epidemiology, Genetic Determinants of Complex Traits related to Cardiovasular Medicine, Coronary Artery Disease related pathway analyses and integrative genomics, Mendelian randomization studies, risk prediction for major adverse cardiovascular events, cardiovascular medicine related pharmacogenomics, ethnic differences in the determinants of Insulin Mediated Glucose Uptake, pharmacoepidemiology of cardiovascular drugs & outcomes
-
Laura Attardi
Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics
Current Research and Scholarly InterestsOur research is aimed at defining the pathways of p53-mediated apoptosis and tumor suppression, using a combination of biochemical, cell biological, and mouse genetic approaches. Our strategy is to start by generating hypotheses about p53 mechanisms of action using primary mouse embryo fibroblasts (MEFs), and then to test them using gene targeting technology in the mouse.
-
Jeffrey Axelrod
Professor of Pathology
Current Research and Scholarly InterestsGenetic and cell biological analyses of signals controlling cell polarity and morphogenesis. Frizzled signaling and cytoskeletal organization.
-
Rosa Bacchetta
Professor (Research) of Pediatrics (Stem Cell Transplantation)
Current Research and Scholarly InterestsIn the coming years, I plan to further determine the genetic and immunological basis of diseases with autoimmunity or immune dysregulation in children. I believe that much can still be learned from the in depth mechanistic studies of pediatric autoimmune diseases. Genomic analysis of the patients' samples has become possible which may provide a rapid indication of altered target molecules. I plan to implement robust functional studies to define the consequences of these genetic abnormalities and bridge them to the patient's clinical phenotype.
Understanding functional consequences of gene mutations in single case/family first and then validating the molecular and cellular defects in other patients with similar phenotypes, will anticipate and complement cellular and gene therapy strategies.
For further information please visit the Bacchetta Lab website:
http://med.stanford.edu/bacchettalab.html -
Laura K. Bachrach
Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emerita
Current Research and Scholarly InterestsPrevention of osteoporosis begins in childhood and adolescence by measures that maximize acquistion of bone mineral during the critical adolescent years. Body mass, calcium nutriture, physical activity, growth and sex steroid hormones, and genetic factors are all thought to be important determinants of bone mass although the relative contribution of each remains controversial.
-
Julie Baker
Professor of Genetics
Current Research and Scholarly InterestsWe examine how cells communicate and function during fetal development. The work in my laboratory focuses on the establishment of specific cell fates using genomics to decipher interactions between chromatin and developmental signaling cascades, between genomes and rapidly evolving cell types, and between genomic copy number variation and gene expression. In recent years we have focused on the vastly understudied biology of the trophoblast lineage, particularly how this lineage evolved.
-
Justin Nathaniel Baker
Deborah E. Addicott - John A. Kriewall and Elizabeth A. Haehl Family Professor of Pediatrics
BioAs a Pediatric Oncologist, Palliative Care Physician, and Phase I and End– of– Life Care Clinical Investigator, I am intimately aware of the distress experienced by children with advanced cancer and the ethical and end– of– life/bereavement issues surrounding their disease progression. I currently serve as the Chief of the Division of Quality of Life and Pediatric Palliative Care here at Stanford, as well as the Director of the Quality of Life for All (QoLA) Program. Additionally, I serve as the Associate Chief Quality Officer for Patient Experience and Holistic Care. In my past career at St Jude, I served as the Director of our large Pediatric Hematology/Oncology Fellowship Program for more than a decade. My research interests include ethical considerations surrounding enrollment in Phase I clinical trials, AYA palliative oncology care, end– of– life decision making, grief and bereavement, integrating palliative care into the ongoing care of children with cancer as well as patient– reported outcomes and pain and symptom control in the context of pediatric oncology care. I have received significant extramural funding for my research, and I have participated in dozens of studies related to pediatric palliative care. I have authored ~300 academic works on a broad array of palliative care subjects. In sum, I am a recognized global expert and leader in the field of Pediatric Palliative Care.
-
Karthik Balakrishnan, MD, MPH, FAAP, FACS
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsDr. Balakrishnan's research focuses on innovative ways to improve and standardize treatments and measure outcomes in complex pediatric airway and aerodigestive conditions , as well as ways to reduce treatment costs and medical errors. By improving outcomes and reducing costs, he aims to improve the value of care, while also optimizing patient and caregiver experience during the care process.
-
Malathi Balasundaram
Clinical Professor, Pediatrics - Neonatal and Developmental Medicine
Current Research and Scholarly InterestsFamily-centered Care in the NICU
-
Zhenan Bao
K. K. Lee Professor, Senior Fellow at the Precourt Institute for Energy and Professor, by courtesy, of Materials Science and Engineering and of Chemistry
BioZhenan Bao joined Stanford University in 2004. She is currently a K.K. Lee Professor in Chemical Engineering, and with courtesy appointments in Chemistry and Material Science and Engineering. She was the Department Chair of Chemical Engineering from 2018-2022. She founded the Stanford Wearable Electronics Initiative (eWEAR) and is the current faculty director. She is also an affiliated faculty member of Precourt Institute, Woods Institute, ChEM-H and Bio-X. Professor Bao received her Ph.D. degree in Chemistry from The University of Chicago in 1995 and joined the Materials Research Department of Bell Labs, Lucent Technologies. She became a Distinguished Member of Technical Staff in 2001. Professor Bao currently has more than 700 refereed publications and more than 80 US patents with a Google Scholar H-index 226.
Bao is a member of the US National Academy of Sciences, National Academy of Engineering, the American Academy of Arts and Sciences and the National Academy of Inventors. Bao was elected a foreign member of the Chinese Academy of Science in 2021. She is a Fellow of AAAS, ACS, MRS, SPIE, ACS POLY and ACS PMSE.
Bao is a member of the Board of Directors for the Camille and Dreyfus Foundation from 2022. She served as a member of Executive Board of Directors for the Materials Research Society and Executive Committee Member for the Polymer Materials Science and Engineering division of the American Chemical Society. She was an Associate Editor for the Royal Society of Chemistry journal Chemical Science, Polymer Reviews and Synthetic Metals. She serves on the international advisory board for Advanced Materials, Advanced Energy Materials, ACS Nano, Accounts of Chemical Reviews, Advanced Functional Materials, Chemistry of Materials, Chemical Communications, Journal of American Chemical Society, Nature Asian Materials, Materials Horizon and Materials Today. She co-founded C3 Nano Co. and PyrAmes, which have produced products used in commercial smartphones and hospitals, respectively. Multiple inventions from her lab have been licensed and served as foundational technologies for several additional start-ups.
Bao was a recipient of the VinFuture Prize Female Innovator 2022, ACS Award of Chemistry of Materials 2022, MRS Mid-Career Award in 2021, AICHE Alpha Chi Sigma Award 2021, ACS Central Science Disruptor and Innovator Prize in 2020, ACS Gibbs Medal in 2020, the Wilhelm Exner Medal from the Austrian Federal Minister of Science in 2018, the L'Oreal UNESCO Women in Science Award North America Laureate in 2017. She was awarded the ACS Applied Polymer Science Award in 2017, ACS Creative Polymer Chemistry Award in 2013 ACS Cope Scholar Award in 2011. She is a recipient of the Royal Society of Chemistry Beilby Medal and Prize in 2009, IUPAC Creativity in Applied Polymer Science Prize in 2008, American Chemical Society Team Innovation Award 2001, R&D 100 Award, and R&D Magazine Editors Choice Best of the Best new technology for 2001. -
Maria Barna
Associate Professor of Genetics
Current Research and Scholarly InterestsOur lab studies how intricate control of gene expression and cell signaling is regulated on a minute-by-minute basis to give rise to the remarkable diversity of cell types and tissue morphology that form the living blueprints of developing organisms. Work in the Barna lab is presently split into two main research efforts. The first is investigating ribosome-mediated control of gene expression genome-wide in space and time during cellular differentiation and organismal development. This research is opening a new field of study in which we apply sophisticated mass spectrometry, computational biology, genomics, and developmental genetics, to characterize a ribosome code to gene expression. Our research has shown that not all of the millions of ribosomes within a cell are the same and that ribosome heterogeneity can diversify how genomes are translated into proteomes. In particular, we seek to address whether fundamental aspects of gene regulation are controlled by ribosomes harboring a unique activity or composition that are tuned to translating specific transcripts by virtue of RNA regulatory elements embedded within their 5’UTRs. The second research effort is centered on employing state-of-the-art live cell imaging to visualize cell signaling and cellular control of organogenesis. This research has led to the realization of a novel means of cell-cell communication dependent on a dense network of actin-based cellular extension within developing organs that interconnect and facilitate the precise transmission of molecular information between cells. We apply and create bioengineering tools to manipulate such cellular interactions and signaling in-vivo.
-
Leandra A. Barnes, MD
Instructor, Dermatology
BioDr. Barnes is a board-certified dermatologist who provides care at Stanford Health Care Dermatology Clinics in Redwood City and Emeryville. She is also an Instructor of Dermatology within the Department of Dermatology at Stanford School of Medicine.
Dr. Barnes specializes in diagnosing and treating a broad range of skin conditions, including hidradenitis suppurativa, skin cancer, and conditions that disproportionally impact people of color. As Co-Director of the Stanford Medicine Hidradenitis Suppurativa Specialty Clinic, her clinical focus includes maximizing awareness of and care options for this condition. Dr. Barnes is also the Founding Director of the Stanford Medicine Skin of Color Program and Director of Advocacy, Equity, and Inclusion in the Department of Dermatology at Stanford Medicine.
Dr. Barnes’ clinical research focuses on identifying the underlying mechanisms associated with the onset and progression of hidradenitis suppurativa. These efforts include research on access to care among different patient populations and studies identifying immune-mediated characteristics of the condition. She is also engaged in efforts to promote broader and more effective outreach initiatives to drive melanoma awareness among minority populations and young children.
Dr. Barnes has published her work in numerous peer-reviewed journals, including the Journal of Investigative Dermatology, JAMA Dermatology, and the Journal of the American Academy of Dermatology. She has also been an invited guest speaker at national and international meetings, including those for the Society of Investigative Dermatology and the World Congress of Dermatology. -
Patrick Barnes
Emeritus Faculty, Acad Council, Miscellaneous
BioDr. Barnes is a pediatric radiologist and pediatric neuroradiologist practicing for 41 years. He has served as the Chief of the Section of Pediatric Neuroradiology and the inaugural Director of the Pediatric MRI and CT Center at the Lucile Packard Children’s Hospital at Stanford (2000-2018), as well as, Professor of Radiology of the Stanford School of Medicine. He is also a founding member of the Child Abuse Task Force and SCAN (suspected child abuse and neglect) Team for LPCH-Stanford. Previously, Dr. Barnes was Chief of the Division of Neuroradiology and inaugural Director of the MRI Center at the Children’s Hospital, Boston, Massachusetts (1986-1999), and Associate Professor of Radiology, Harvard Medical School. Prior to that he was a pediatric radiologist and Chief of Pediatric Neuroradiology, as well as, inaugural Co-Director of the MRI Center at the Oklahoma Children’s Memorial Hospital and Oklahoma Memorial Hospital (1977-1986), and Associate Professor of the University of Oklahoma College of Medicine ( see CV, Biosketch, Resume attached, Patrick D. Barnes,MD <en.m..wikipedia.org>).
The main focus of his clinical, teaching, and research career has been the development and implementation of magnetic resonance imaging (MRI) as the most advanced and non-invasive technology for imaging of injury to the developing central nervous system and related body systems of the fetus, newborn, infant, and child, including for the assessment of child abuse and the mimics of child abuse. He co-authored the first comprehensive textbook on the utilization of US, CT, and MRI in pediatric neuroradiology (Wolpert S, Barnes P: MRI in Pediatric Neuroradiology, Mosby-Year Book,1992). Dr. Barnes was the first dedicated children’s hospital-based pediatric neuroradiologist in Northern California (LPCH-Stanford 2000). He is Co-Founder and Past President of the American Society of Pediatric Neuroradiology (1998; see CV), and past Chair of the Child Abuse Task Force of the Society for Pediatric Radiology (2007; see Resume). More recently, he has served as pediatric neuroradiology consultant and lead central reviewer for the Neonatal Research Network (NRN) of the NIH / NICHD for their multicenter projects assessing the utility of imaging technology for preterm and term fetal and neonatal brain injury, including interventions and outcomes (2006-2018; see Biosketch).
“It has been my inspiration and honor not only to contribute to the training and education of students, residents, and fellows from all backgrounds, and proudly including those serving in our Armed Forces, but also to teach, mentor, and promote diversity, of future leaders in pediatric radiology and neuroradiology (see CV). It has also been my honor to work every day with a talented and diverse team of radiologic technology, information technology, physician, nursing, child life, scheduling coordinater, administrative, management, and scientific research professionals, all dedicated to the quality and compassionate care of children and families who come to us from all social and cultural communities across our nation and the world.” -
Donald Barr
Professor (Teaching) of Pediatrics (General Pediatrics), Emeritus
BioDonald Barr is a Professor of Pediatrics in the Stanford School of Medicine, and Professor by Courtesy in the Graduate School of Education. He teaches in the Undergraduate Program in Human Biology, where he helped to found Human Biology's curriculum in health policy. His research has studied the effect of the organizational structure of the U.S. medical care delivery system on the quality of primary care. He has also studied cultural and linguistic barriers to health care access for low-income patients, and factors associated with higher rates of attrition from pre-medical studies among minority students at Stanford and other universities. The fourth edition of his book, Introduction to U.S. Health Policy: The Organization, Financing, and Delivery of Health Care in America, was published in 2016. The third edition of his book, Health Disparities in the United States: Social Class, Race, Ethnicity and the Social Determinants of Health, was published in 2019. In June 2003 Dr. Barr was awarded the Lloyd W. Dinkelspiel Award for Distinctive Contribution to Undergraduate Education at Stanford University. In 2006 he received the Miriam Aaron Roland Prize, which recognizes Stanford faculty who engage and involve students in integrating academic scholarship with significant and meaningful volunteer service to society.
-
Richard Barth
Professor of Radiology (Pediatric Radiology) and, by courtesy, of Obstetrics and Gynecology (Maternal Fetal Medicine)
Current Research and Scholarly InterestsMagnetic Resonance Imaging and Sonographic diagnosis of fetal anomalies.
Focus interest in the diagnosis and conservative (non-surgical and minimal radiation) management of congenital broncho pulmonary malformations.
Imaging of appendicitis in children.
Sonography of the pediatric testis. -
Dorsey Bass
Associate Professor of Pediatrics (Gastroenterology), Emeritus
Current Research and Scholarly InterestsOur laboratory is interested in the pathophysiology, immunology, and epidemiology of viral gastroenteritis.
-
Hannah Bassett
Clinical Associate Professor, Pediatrics
Current Research and Scholarly InterestsUnderstanding how to implement real time patient-centered healthcare cost transparency in the acute care setting and how this transparency effects patient and system-level outcomes.
Understanding how to best decrease unnecessary variation in clinical care through implementation of clinical effectiveness tools. -
Glaivy Batsuli, MD
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsHemophilia is a rare inherited X-linked bleeding disorder characterized by the deficiency of blood clotting proteins factor VIII or factor IX. These individuals are at risk for spontaneous bleeds and trauma or surgery-induced bleeding. There have been remarkable advancements in the management of hemophilia to prevent these bleeding episodes and improve quality of life. However, the presence of neutralizing antibodies, called inhibitors, still dictates access to novel therapies such as factor replacement for bleed management and now FDA-approved gene therapies. The Batsuli Lab is focused on elucidating mechanisms of the immune response to blood coagulation proteins in bleeding disorders in order to develop strategies and therapeutics for inhibitor prevention and tolerance induction.
Dr. Batsuli's clinical research interests also include clinical trial participation for novel therapeutics & interventions in bleeding disorders such as hemophilia and von Willebrand disease in addition to coagulation issues & outcomes in ultra-rare bleeding disorders and sickle cell disease.
